Custom Recombinant Antibody Production for Phosphorylation Research
Home / Services / Custom Antibody for Phosphorylation Research / Custom Recombinant Antibody Production for Phosphorylation Research Custom Recombinant Antibody Production for Phosphorylation Research
INQUIRYCreative BioMart is confident to provide our customers with high-quality recombinant antibodies for their kinase/phosphatase biology research and pharmaceutical development projects. We offer a fully custom service package from gene synthesis to antibody characterization to ensure that our customers receive the required antibodies for their downstream applications as soon as possible.
Background
Recombinant antibodies are produced in vitro by recombinant DNA technology using the genes encoding antibodies as the starting material. These genes are cloned into high-yield expression vectors and then introduced into expression hosts to generate recombinant antibodies. Not only full-length antibodies but also antibody fragments such as Fab/scFv/sdAb can be produced. Recombinant antibodies offer many advantages and are therefore widely used in life sciences and medicine. They have been developed for a variety of applications such as ELISA, Western blot, flow cytometry, immunofluorescence, immunohistochemistry, and ChIP. Recombinant monoclonal and polyclonal antibodies are already powerful tools in kinase/phosphatase biology to elucidate the regulation mechanism of phosphorylation and develop new drugs targeting kinases or phosphatases.
Figure 1. Schematic diagram of yeast two- and three-hybrid assay design with a representative vector map of pY3HS for ectopic expression of the recombinant antibody. (Zábrady M, et al., 2014)
Advantages of Recombinant Antibodies
- Effectively obviate the need for animal usage and elimination of ethical issues.
- High specificity, sensitivity and reproducibility.
- High purity and affinity.
- Easy to engineer and manufacture with short cycles.
- High consistency between batches.
- Ease of scalability and continuity of supply.
- Fusion with drugs and/or toxins for further development of the medical applications.
- Cost-effective and suitable for high-throughput production.
Capabilities
Creative BioMart has extensive experience in custom recombinant antibody production. We have advanced expression platforms and professional scientific team to maximize the chance of producing recombinant antibodies with high specificity, sensitivity and reproducibility within a short period of time. We are capable of manufacture antibodies in large quantities.
Service Options
Creative BioMart offers a wide range of flexible and customized service options to handle projects of all levels of complexity. Whether the production process is challenging or has specific requirements, we will do our best to optimize the custom project to perfectly meet your research requirements.
| Service Options | ||
| Fab antibody production | scFv antibody production | Single-domain antibody production |
| Chimeric antibody production | Bispecific antibody production | Transient antibody production |
| Recombinant antibody Reformatting | High-throughput antibody production | Large-scale antibody production |
| Expression Platforms | ||
| Bacteria | Yeast | Filamentous fungi |
| Protozoa | Insect cells | Algal |
| Mammalian cells | Transgenic animals | Transgenic plants |
If you can't find what you are looking for in the options above, please fill out the online inquiry form and let us know more details.
Standard Service Process
Highlights
Creative BioMart provides comprehensive and flexible custom recombinant antibody production services to meet the individual needs of our customers. Our advanced technology platform coupled with a large product portfolio has enabled us to successfully complete numerous challenging projects, helping our customers save time and effort. A large collection of ready-to-use recombinant antibodies is also available.
If you are interested in our services or products, please do not hesitate to contact us.
Reference
- Zábrady M, et al. Targeted in vivo inhibition of specific protein–protein interactions using recombinant antibodies. PloS one, 2014, 9(10): e109875.